DCLK3 and neoplasm: The approval of these two monoclonal antibodies gives promise to the potential of the currently available AM1-, AM2-, and CLR-targeting antibodies with proved tumor growth-inhibitory activity in preclinical models of colon, glioblastoma, PDAC, lung and breast cancer (120, 141, 157, 196).